{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Advanced+or+Metastatic+Solid+Tumor+Malignancies&page=2", "query": { "condition": "Advanced or Metastatic Solid Tumor Malignancies", "page": 2 }, "page_size": 10 }, "pagination": { "page": 2, "page_size": 10, "total_count": 864, "total_pages": 87, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Advanced+or+Metastatic+Solid+Tumor+Malignancies&page=3&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Advanced+or+Metastatic+Solid+Tumor+Malignancies&page=1&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-08T06:58:36.663Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT04574583", "title": "Phase I/II Trial Investigating the Safety, Tolerability, Pharmacokinetics, Immune and Clinical Activity of SX-682 in Combination With BinTrafusp Alfa (M7824 or TGF-beta \"Trap\"/PD-L1) With CV301 TRICOM in Advanced Solid Tumors (STAT)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Metastatic Cancer", "Solid Tumors" ], "interventions": [ { "name": "SX-682", "type": "DRUG" }, { "name": "M7824", "type": "DRUG" }, { "name": "MVA-BN-CV301", "type": "BIOLOGICAL" }, { "name": "recombinant fowlpox viral (FPV)-CV301", "type": "BIOLOGICAL" } ], "intervention_types": [ "DRUG", "BIOLOGICAL" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 12, "start_date": "2020-11-24", "completion_date": "2023-05-19", "has_results": true, "last_update_posted_date": "2025-02-03", "last_synced_at": "2026-10-08T06:58:36.663Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT04574583" }, { "nct_id": "NCT02705105", "title": "Study of Mogamulizumab + Nivolumab in Subjects w/Locally Advanced or Metastatic Solid Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Solid Tumor", "Cancer", "Carcinoma", "Hepatocellular Carcinoma", "HCC" ], "interventions": [ { "name": "Mogamulizumab + Nivolumab", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Kyowa Kirin, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 114, "start_date": "2016-02", "completion_date": "2018-10-10", "has_results": true, "last_update_posted_date": "2024-04-25", "last_synced_at": "2026-10-08T06:58:36.663Z", "location_count": 15, "location_summary": "Gilbert, Arizona • Greenbrae, California • Los Angeles, California + 12 more", "locations": [ { "city": "Gilbert", "state": "Arizona" }, { "city": "Greenbrae", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Jacksonville", "state": "Florida" }, { "city": "Augusta", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT02705105" }, { "nct_id": "NCT01311713", "title": "Study to Determine the Maximum Tolerated Dose of the PARP Inhibitor CEP-9722 in Participants With Solid Tumors", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Solid Tumors" ], "interventions": [ { "name": "CEP-9722", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Teva Branded Pharmaceutical Products R&D, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 45, "start_date": "2011-05-02", "completion_date": "2013-10-16", "has_results": true, "last_update_posted_date": "2024-01-30", "last_synced_at": "2026-10-08T06:58:36.663Z", "location_count": 4, "location_summary": "Aurora, Colorado • Detroit, Michigan • St Louis, Missouri + 1 more", "locations": [ { "city": "Aurora", "state": "Colorado" }, { "city": "Detroit", "state": "Michigan" }, { "city": "St Louis", "state": "Missouri" }, { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT01311713" }, { "nct_id": "NCT04628780", "title": "Study to Test the Safety and Tolerability of PF-07209960 in Advanced or Metastatic Solid Tumors", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Non-small-cell Lung Cancer", "Squamous Cell Carcinoma of the Head and Neck", "Renal Cell Carcinoma", "Urothelial Carcinoma", "Colorectal Carcinoma", "Ovarian Carcinoma" ], "interventions": [ { "name": "PF-07209960", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Pfizer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 37, "start_date": "2020-12-16", "completion_date": "2023-05-26", "has_results": true, "last_update_posted_date": "2024-07-29", "last_synced_at": "2026-10-08T06:58:36.663Z", "location_count": 13, "location_summary": "Duarte, California • Los Angeles, California • Santa Monica, California + 3 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Duarte", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Santa Monica", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04628780" }, { "nct_id": "NCT07492680", "title": "A Study of BMS-986504 Monotherapy and in Combination With Other Agents in Participants With Advanced and/or Metastatic Solid Tumors With Homozygous MTAP Deletion (MountainTAP-5)", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Solid Tumors" ], "interventions": [ { "name": "BMS-986504", "type": "DRUG" }, { "name": "Daraxonrasib", "type": "DRUG" }, { "name": "Nivolumab + Relatlimab FDC", "type": "DRUG" }, { "name": "Temozolomide", "type": "DRUG" }, { "name": "Pumitamig", "type": "DRUG" }, { "name": "Pemetrexed", "type": "DRUG" }, { "name": "Carboplatin", "type": "DRUG" }, { "name": "Nab-paclitaxel", "type": "DRUG" }, { "name": "Gemcitabine", "type": "DRUG" }, { "name": "Paclitaxel", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Bristol-Myers Squibb", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 260, "start_date": "2026-07-27", "completion_date": "2032-05-20", "has_results": false, "last_update_posted_date": "2026-10-06", "last_synced_at": "2026-10-08T06:58:36.663Z", "location_count": 16, "location_summary": "San Francisco, California • Aurora, Colorado • Atlanta, Georgia + 10 more", "locations": [ { "city": "San Francisco", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Baltimore", "state": "Maryland" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT07492680" }, { "nct_id": "NCT07488676", "title": "A Study of ASP546C in Adults With Gastroesophageal Cancer, Pancreatic Cancer or Other Solid Tumors", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Gastric or Gastro-esophageal Junction (GEJ) Adenocarcinoma", "Pancreatic Adenocarcinoma" ], "interventions": [ { "name": "ASP546C", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Astellas Pharma Global Development, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 150, "start_date": "2026-05-04", "completion_date": "2029-07-31", "has_results": false, "last_update_posted_date": "2026-09-22", "last_synced_at": "2026-10-08T06:58:36.663Z", "location_count": 18, "location_summary": "Birmingham, Alabama • Los Angeles, California • Miami, Florida + 15 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Los Angeles", "state": "California" }, { "city": "Miami", "state": "Florida" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Indianapolis", "state": "Indiana" } ], "official_url": "https://clinicaltrials.gov/study/NCT07488676" }, { "nct_id": "NCT04457778", "title": "First in Human Study of M6223", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Metastatic Solid Tumors" ], "interventions": [ { "name": "M6223", "type": "DRUG" }, { "name": "Bintrafusp alfa", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "EMD Serono Research & Development Institute, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 58, "start_date": "2020-07-10", "completion_date": "2023-06-23", "has_results": true, "last_update_posted_date": "2026-05-04", "last_synced_at": "2026-10-08T06:58:36.663Z", "location_count": 3, "location_summary": "Nashville, Tennessee • Houston, Texas • San Antonio, Texas", "locations": [ { "city": "Nashville", "state": "Tennessee" }, { "city": "Houston", "state": "Texas" }, { "city": "San Antonio", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT04457778" }, { "nct_id": "NCT03489343", "title": "Sym023 (Anti-TIM-3) in Patients With Advanced Solid Tumor Malignancies or Lymphomas", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Metastatic Cancer", "Solid Tumor", "Lymphoma" ], "interventions": [ { "name": "Sym023", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Symphogen A/S", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 24, "start_date": "2018-05-24", "completion_date": "2020-06-03", "has_results": true, "last_update_posted_date": "2021-10-12", "last_synced_at": "2026-10-08T06:58:36.663Z", "location_count": 3, "location_summary": "Grand Rapids, Michigan • Houston, Texas • San Antonio, Texas", "locations": [ { "city": "Grand Rapids", "state": "Michigan" }, { "city": "Houston", "state": "Texas" }, { "city": "San Antonio", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT03489343" }, { "nct_id": "NCT03465722", "title": "(VOYAGER) Study of Avapritinib vs Regorafenib in Patients With Locally Advanced Unresectable or Metastatic GIST", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "GIST" ], "interventions": [ { "name": "avapritinib", "type": "DRUG" }, { "name": "regorafenib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Blueprint Medicines Corporation", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 476, "start_date": "2018-03-26", "completion_date": "2021-09-15", "has_results": true, "last_update_posted_date": "2022-10-06", "last_synced_at": "2026-10-08T06:58:36.663Z", "location_count": 30, "location_summary": "Phoenix, Arizona • Santa Monica, California • Aurora, Colorado + 26 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Santa Monica", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Boulder", "state": "Colorado" }, { "city": "Washington D.C.", "state": "District of Columbia" } ], "official_url": "https://clinicaltrials.gov/study/NCT03465722" }, { "nct_id": "NCT00127829", "title": "Study Evaluating Gefitinib (IRESSA®) in Subjects With Solid Malignancies That Are Locally Advanced, Recurrent or Metastatic", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Tumors" ], "interventions": [ { "name": "Gefitinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AstraZeneca", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 66, "start_date": "2005-07", "completion_date": "2008-01", "has_results": false, "last_update_posted_date": "2009-04-23", "last_synced_at": "2026-10-08T06:58:36.663Z", "location_count": 2, "location_summary": "Los Angeles, California • Palm Springs, California", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Palm Springs", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00127829" } ] }